Market Place
Sourcing Support
Effector Therapeutics Winds Down After Mid-Stage Oncology Fail
24 Jun 2024 //
FIERCE BIOTECH
eFFECTOR Therapeutics Q1 2024 Financials And Corporate Update
09 May 2024 //
GLOBENEWSWIRE
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
09 Apr 2024 //
GLOBENEWSWIRE
eFFECTOR`s lead lung cancer program falls through, stock crashes
04 Apr 2024 //
ENDPTS
eFFECTOR Reports Fourth Quarter and Full Year 2023 Financial Results
25 Mar 2024 //
GLOBENEWSWIRE
eFFECTOR to Present at Oppenheimer 34th Annual Healthcare Conference
05 Feb 2024 //
GLOBENEWSWIRE
eFFECTOR Announces Closing of $15 Million Registered Direct Offering
29 Jan 2024 //
GLOBENEWSWIRE
eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering
25 Jan 2024 //
GLOBENEWSWIRE
eFFECTOR Therapeutics Announces Reverse Stock Split
09 Jan 2024 //
GLOBENEWSWIRE
eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
09 Jan 2024 //
GLOBENEWSWIRE
eFFECTOR Therapeutics Announces Data from Phase 2 Expansion Cohorts of Zotatifin
08 Dec 2023 //
GLOBENEWSWIRE
eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin
28 Nov 2023 //
GLOBENEWSWIRE
eFFECTOR to Present Data from Phase 2 Expansion Cohorts of Zotatifin
15 Nov 2023 //
GLOBENEWSWIRE
eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
eFFECTOR to Participate in Fireside Chat at 2023 Stifel Healthcare Conference
06 Nov 2023 //
GLOBENEWSWIRE
eFFECTOR to Collaborate with Northwestern University Division of Hematology
24 Oct 2023 //
GLOBENEWSWIRE
eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors
11 Sep 2023 //
GLOBENEWSWIRE
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
30 Aug 2023 //
GLOBENEWSWIRE
eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
eFFECTOR Announces $8.7M Registered Direct Offering Priced Under Nasdaq Rules
07 Jun 2023 //
GLOBENEWSWIRE
eFFECTOR Announces Closing of $7.5 Million Registered Direct Offering
31 May 2023 //
GLOBENEWSWIRE
eFFECTOR Therapeutics Announces $7.5 Million Registered Direct Offering
26 May 2023 //
GLOBENEWSWIRE
eFFECTOR reports interim data updates from cancer combo expansion cohort
26 May 2023 //
CLINICAL TRIALS ARENA
eFFECTOR Reports Positive Data Updates from Phase 2 Evaluating Zotatifin
25 May 2023 //
GLOBENEWSWIRE
eFFECTOR Therapeutics Reports1Q 2023 FYR and Provides Corporate Update
09 May 2023 //
GLOBENEWSWIRE
eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference
08 May 2023 //
GLOBENEWSWIRE
eFFECTOR to Present Updated Clinical Data Ph 2 Expansion Cohorts for Zotatifin
26 Apr 2023 //
GLOBENEWSWIRE
Effector to Collaborate with Stanford on PII Study with ER+ Breast Cancer
11 Apr 2023 //
GLOBENEWSWIRE
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
28 Mar 2023 //
GLOBENEWSWIRE
eFFECTOR Therapeutics Announces Results from Phase 1b Trial of Zotatifin
21 Feb 2023 //
GLOBENEWSWIRE
eFFECTOR reports positive data from trial of zotatifin for Covid-19
21 Feb 2023 //
CLINICAL TRIALS ARENA
eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference
30 Jan 2023 //
GLOBENEWSWIRE
eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin
05 Jan 2023 //
GLOBENEWSWIRE
eFFECTOR Reports 3Q 2022 Financial Results and Provides Corporate Update
07 Nov 2022 //
GLOBENEWSWIRE
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
31 Oct 2022 //
GLOBENEWSWIRE
eFFECTOR Completes Enrollment in Cohorts of Phase 1b Trial of Zotatifin
26 Oct 2022 //
GLOBENEWSWIRE
eFFECTOR Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer
26 Sep 2022 //
GLOBENEWSWIRE
eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology
21 Sep 2022 //
GLOBENEWSWIRE
eFFECTOR Doses First Patient in Second Cohort of Pha 1b Trial of Zotatifin
14 Sep 2022 //
GLOBENEWSWIRE
eFFECTOR Therapeutics to Present at H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
GLOBENEWSWIRE
eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer
08 Aug 2022 //
GLOBENEWSWIRE
eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference
07 Jun 2022 //
GLOBENEWSWIRE
eFFECTOR Reports Positive Interim Results in Zotatifin PI/II Trial at ASCO 2022
05 Jun 2022 //
GLOBENEWSWIRE
eFFECTOR to Present Interim Data from Ongoing Zotatifin PI/II Trial
26 May 2022 //
GLOBENEWSWIRE
eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
02 May 2022 //
GLOBENEWSWIRE
eFFECTOR Therapeutics Announces Transition in Clinical Leadership
04 Apr 2022 //
GLOBENEWSWIRE
eFFECTOR Tx Reports Q4 and FY 2021 Financial Results
16 Mar 2022 //
GLOBENEWSWIRE
eFFECTOR Therapeutics to Present at 2022 BIO CEO & Investor Conference
09 Feb 2022 //
GLOBENEWSWIRE
eFFECTOR Therapeutics Provides Pipeline and Business Updates
24 Jan 2022 //
GLOBENEWSWIRE
eFFECTOR Therapeutics to Participate in The JMP Securities Hematology
22 Nov 2021 //
GLOBENEWSWIRE
eFFECTOR Therapeutics Reports Third Quarter 2021 Financial Results
08 Nov 2021 //
GLOBENEWSWIRE
Effector gains 22% after-hours on encouraging zotatifin data
08 Oct 2021 //
SEEKINGALPHA
eFFECTOR Therapeutics to Participate in 2021 Cantor Healthcare Conference
16 Sep 2021 //
GLOBENEWSWIRE
eFFECTOR`s SPAC deal is back after going from launch to merger in 4 months
14 Sep 2021 //
ENDPTS
eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company
25 Aug 2021 //
GLOBENEWSWIRE
Locust Walk Acquisition and eFFECTOR Therapeutics announce business combination
24 Aug 2021 //
GLOBENEWSWIRE
eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts on Zotatifin
04 Aug 2021 //
GLOBENEWSWIRE
eFFECTOR Doses First Patient COVID19 Phase 1b Clinical Trial as a HostTargeted
22 Jul 2021 //
GLOBENEWSWIRE
